Related references
Note: Only part of the references are listed.Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study
Paolo Ventura et al.
LIVER INTERNATIONAL (2022)
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran
Paolo Ventura et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
Bruce Wang et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients
Juan Buendia-Martinez et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians
Karl E. Anderson et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2021)
Hyperhomocysteinemia in patients with acute porphyrias: a possible effect of ALAS1 modulation by siRNAm therapy and its control by vitamin supplementation
Andrea Ricci et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)
Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase
Daphne Vassiliou et al.
JOURNAL OF INTERNAL MEDICINE (2021)
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Laurent Gouya et al.
HEPATOLOGY (2020)
Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?
Paolo Ventura et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the envision open label extension
Eliane Sardh et al.
JOURNAL OF HEPATOLOGY (2020)
Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs)
Herbert L. Bonkovsky et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Eliane Sardh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Acute hepatic porphyrias: Current diagnosis & management
Karl E. Anderson
MOLECULAR GENETICS AND METABOLISM (2019)
Acute Hepatic Porphyrias: Review and Recent Progress
Bruce Wang et al.
HEPATOLOGY COMMUNICATIONS (2019)
Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations
Amy Simon et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)
Update review of the acute porphyrias
Penelope E. Stein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Acute Hepatic Porphyrias: Recommendations for Evaluation and Long-Term Management
Manisha Balwani et al.
HEPATOLOGY (2017)
Porphyria
D. Montgomery Bissell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study
Hetanshi Naik et al.
MOLECULAR GENETICS AND METABOLISM (2016)
The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference
Claire M. Nolan et al.
THORAX (2016)
How Much Do Cancer-Related Symptoms Contribute to Health-Related Quality of Life in Lung and Colorectal Cancer Patients? A Report From the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium
Kelly M. Kenzik et al.
CANCER (2015)
Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification
Amy Chan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Estimation of Minimal Clinically Important Difference in EQ-5D Visual Analog Scale Score After Pulmonary Rehabilitation in Subjects With COPD
Andrea Zanini et al.
RESPIRATORY CARE (2015)
Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias Consortium
Herbert L. Bonkovsky et al.
AMERICAN JOURNAL OF MEDICINE (2014)
The minimal clinically important difference in the Oxford knee score and Short Form 12 score after total knee arthroplasty
N. D. Clement et al.
KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY (2014)
Acute intermittent porphyria: fatal complications of treatment
P. E. Stein et al.
CLINICAL MEDICINE (2012)
Minimum clinically important difference in pain, disability, and quality of life after neural decompression and fusion for same-level recurrent lumbar stenosis: understanding clinical versus statistical significance Clinical article
Scott L. Parker et al.
JOURNAL OF NEUROSURGERY-SPINE (2012)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease
J Müller-Nordhorn et al.
HEART (2004)